|
|
|
|
|
Sponsored by: |
Novartis |
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00110240 |
This study is not being conducted in the United States. The purpose of this study is to assess the safety and effectiveness of vildagliptin, an unapproved drug, compared to acarbose in lowering overall blood glucose levels in people with type 2 diabetes who have not been previously treated with drug therapy to lower their blood sugar.
Condition | Intervention | Phase |
Diabetes Mellitus, Type 2 |
Drug: vildagliptin |
Phase III |
MedlinePlus related topics: | Diabetes |
ChemIDplus related topics: | Vildagliptin Acarbose |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Efficacy and Safety of Vildagliptin Compared to Acarbose in Drug Naive Patients With Type 2 Diabetes |
Estimated Enrollment: | 660 |
Study Start Date: | April 2005 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | CLAF237A2323 |
First Received: | May 4, 2005 |
Last Updated: | January 2, 2007 |
ClinicalTrials.gov Identifier: | NCT00110240 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
|